Table 1 hVEGF concentrations, platelet counts and trough bevacizumab concentrations in patients 1–8
Patient number | Tumour type | VEGF concentration C1 (pg ml−1) | VEGF concentration on-treatment (pg ml−1) | Platelet count C1 (× 109 l−1) | Platelet count on-treatment (× 109 l−1) | Bevacizumab concentration ( μ g ml−1) |
|---|---|---|---|---|---|---|
1 | Liver | 373.8 | 44.1 | 194 | 282 | 86.9 |
2 | Ovarian | 316.8 | 71.1 | 206 | 193 | 156.1 |
3 | Neuroendocrine | 178.1 | 72.3 | 157 | 184 | 74.2 |
4 | Ovarian | 2952.9 | 48.1 | 1157 | 1162 | 18.9 |
5 | Renal | 469.9 | 57.5 | 185 | 231 | 35.2 |
6 | Ovarian | 168.2 | 46.7 | 183 | 195 | 82.8 |
7 | Breast | 200 | 91 | 246 | 223 | 41.2 |
8 | Bladder | 388.5 | 34.5 | 446 | 445 | 24.6 |
Mean (±s.d.) | 631.0 (±944.6) | 58.2 (±18.7) | 346.8 (±339.9) | 364.4 (±333.4) | 65.0 (±45.3) |
